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Background/Aims: To investigate the degree of cyclooxygenase-2 (COX-2) protein expression in chronic
hepatitis and cirrhosis.
Methods: COX-2 protein expression was evaluated in 43 cases of chronic hepatitis and 24 cases of cirrhosis
using immunohistochemical techniques. The COX-2 immunohistochemical staining score was assessed using the
scoring systems of Pazirandeh et al and Qiu et al. and each scoring system was based on a sum of the
parameters of staining intensity and distribution. 
Results: The mean COX-2 expression scores in chronic hepatitis and cirrhosis were 2.5 ± 1.3 vs. 3.3 ± 1.1 (p =
0.008), and 3.2 ± 2.0 vs. 4.5 ± 1.7 (p = 0.006), respectively, based on the Pazirandeh et al. and Qiu et al. scoring
systems. The percentage samples of high COX-2 expression score (4 to 5) in chronic hepatitis and cirrhosis were
16.3% vs. 45.8% (p = 0.022), and 23.3% vs. 50% (p = 0.021), respectively, based on the two scoring systems.
The mean COX-2 expression scores based on the severity of hepatic fibrosis scored using Ishak's modified
staging system (fibrosis score 0 to 3 vs. 4 to 6) were 2.4 ± 1.3 vs. 3.2 ± 1.1 (p = 0.009), and 3.1 ± 2.0 vs. 4.3 ± 1.8
(p = 0.009), respectively, based on the two scoring systems. 
Conclusions: COX-2 expression was significantly higher in liver cirrhosis group than in chronic hepatitis. COX-2
expression scores according to Ishak's staging was significantly higher in the advanced fibrosis group. COX-2 may
play a role in the progression of hepatic fibrosis. (Korean J Intern Med 2010;25:364-371)
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INTRODUCTION
Cyclooxygenase (COX)-1 and COX-2 are key enzymes
that control the rate-limiting step in the conversion of
arachidonic acid to prostaglandins. COX-1 is present
constitutively in a number of different tissues, including
the stomach, platelets, kidneys, and endothelial cells. It is
responsible for regulating various physiological functions,
including cytoprotection of the stomach, integrity of renal
function, and platelet aggregation. Expression of the COX-
2 enzyme is inducible through inflammatory and
neoplastic processes involving a variety of factors such as
mitogens, cytokines, growth factors, and tumor promoters
[1-3]. COX-2 overexpression has been reported in various
cancer models, including colon [2,3], esophageal [4],
gastric [5], pancreatic [6], lung [7], and breast [8] cancers,
as well as hepatocellular carcinoma (HCC) [9-12].
Hepatocarcinogenesis is a multistep process involving
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repeating cycles of hepatocyte inflammation, destruction,
regeneration, and unregulated proliferation [13-17].
Although the exact pathogenesis of HCC is not fully
understood, these changes are believed to be due, in part,
to aberrant expression of various tumor suppressor genes,
oncogenes, growth factors, and the COX-2 enzyme [17]. In
addition to HCC, COX-2 is also upregulated in the liver
under conditions of chronic viral hepatitis or cirrhosis
[18,19]. Moreover, growing evidence indicates that COX-2
plays an important role in several signaling pathways in
hepatic stellate cells (HSCs). Specifically, COX-2 is
expressed in serum-starved HSCs in vitro, and its
expression is further upregulated by cytokines [20,21].
HSC proliferation and migration stimulated by platelet-
derived growth factor (PDGF) are associated with COX-2
induction and increased prostaglandin E2 production
[21,22]. 
To clarify the role of COX-2 in the progression of liver
fibrosis, the effects of treatment with COX-2 inhibitors
have been investigated in animal models. The effects of
COX-2 inhibitors on liver fibrosis, however, are controver-
sial, with reports of both exacerbation [23-25] and
amelioration [26-29] of fibrogenesis following COX-2
treatment. Direct comparisons of COX-2 expression in
chronic hepatitis and cirrhosis have only rarely been
reported, and a definitive role for COX-2 in fibrosis has
not been fully elucidated. The present study was conducted
to assess the degree of COX-2 expression in chronic
hepatitis and liver cirrhosis and to identify differences in
COX-2 expression associated with the severity of liver
disease.
METHODS
Patients and liver specimens  
Liver biopsies were selected from 91 cases between May
2003 and December 2006. The samples involved 50 cases
of chronic hepatitis and 41 cases of liver cirrhosis.
Following the exclusion of biopsies with inadequate
material (n = 24), 67 cases were selected for staining: 43
cases of chronic hepatitis (hepatitis B/C, 21/22) and 24
cases of liver cirrhosis (hepatitis B/C/unknown, 14/6/4).
Informed consent was obtained from each patient or from
a family member.
COX-2 immunohistochemical staining 
Biopsy samples were fixed in 10% neutral formalin and
embedded in paraffin. Slide-mounted tissue sections were
deparaffinized in xylene for more than 20 min and then
hydrated sequentially in 100, 95, 90, and 80% ethanol
solutions. After rinsing with water for 5 minutes, the
sections were pretreated with EDTA buffer (pH 6.0) for 12
minutes using a microwave antigen-retrieval procedure.
After rinsing, the endogenous peroxidase activity was
blocked by treatment with 3% hydrogen peroxide for 20
minutes. A primary mouse monoclonal antibody against
COX-2 (1 : 100; Cayman Chemical, Ann Arbor, MI, USA)
was applied to the sections for 1 hour at room temperat-
ure. After rinsing with phosphate-buffered saline (PBS),
the slides were incubated with a secondary antibody for 10
minutes at room temperature and then rinsed with PBS.
The sections were incubated in tertiary anti-horseradish
peroxidase (HRP) conjugate for 10 minutes, rinsed in
PBS, and incubated with aminoethyl carbazole (AEC) for
10 minutes. After counterstaining with Meyer's
Figure 1. Cyclooxygenase-2 immunohistochemical staining in colon cancer. (A) The positive control showed staining in the cytoplasm
of colon cancer cells. (B) The negative control showed no staining (× 200).
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hematoxylin, the slides were mounted with Crystal
mount
® (Biomeda, Foster City, CA, USA). The colon
cancer tissue for the negative control slide was processed
in the same way, except that samples were incubated in
PBS instead of the primary antibody solution. Colon
cancer tissue sections with known COX-2 staining status
were used as positive or negative COX-2 staining controls
(Fig. 1).
COX-2 immunohistochemical staining score
All of the stained biopsy samples were reviewed and
interpreted by an expert hepatopathologist. Histological
grading and staging were assessed using the Ishak's
system [30]. The COX-2 immunohistochemical staining
score was assessed using the scoring systems by
Pazirandeh et al. [19] and by Qiu et al. [31], which are both
based on a sum of two parameters: staining intensity and
staining distribution. In the scoring system of Pazirandeh
et al. [19], COX-2 staining intensity in tissue was scored
using a scale of 0 to 3 (0 = no staining, 1 = weak staining, 2
= moderate staining, and 3 = strong staining), and the
distribution of COX-2 staining was scored using a scale of
0 to 2 (0 = no staining, 1 = focal/patchy staining, 2 =
diffuse staining). Each tissue was evaluated for the sum of
these two parameters and assessed by the degree of COX-
2 immunoreactivity using a qualitative score that ranged
from 0 to 5. Scores between 0 and 3 were categorized as
low COX-2 expression, and scores of 4 and 5 were
categorized as high COX-2 expression. 
The scoring system described by Qiu et al. [31] was used
as follows. The intensity of staining for COX-2 in tissues
was scored on a scale of 0 to 3 (0 = negative staining, 1 =
weakly positive staining, 2 = moderately positive staining,
and 3 = strongly positive staining). The percentage of
positive cells in each specimen was estimated and scored
on a scale of 0 to 4 (0 = negative, 1 = positive staining in 1
to 25% of cells counted, 2 = positive in 26 to 50%, 3 =
positive in 51 to 75%, and 4 = positive in 76 to 100%).
Each section was evaluated for the sum of these two
parameters, with combined scores between 0 and 4
indicating low COX-2 expression and scores from 5 to 7
indicating high COX-2 expression. In this report, the
scoring system of Pazirandeh et al. [19] is referred to as
'sum 1,' and the scoring system of Qiu et al. [31] as 'sum 2.' 
Histological staging according to fibrosis
Ishak's system [30] was used to evaluate possible
correlations between COX-2 expression and the stage of
hepatic fibrosis. Scores for fibrosis stage ranged from 0 to
6. To identify the correlation of COX-2 expression with the
stage of fibrosis, scores of COX-2 expression according to
the degree of hepatic fibrosis were evaluated by
categorization into a low-fibrosis (Ishak's score 1 to 3; n =
30) and a high-fibrosis stage (Ishak's score 4 to 6; n = 37). 
Statistical analysis
The correlation coefficient was used to assess the
relationship between the sum 1 and sum 2 scoring
systems. The Mann-Whitney U test was used to compare
patient characteristics and COX-2 expression scores
between cases of chronic hepatitis and cirrhosis. Pearson's
chi-square test was used to compare the percentage of
high COX-2 expression between chronic hepatitis and
cirrhosis. Student's t test was used to compare COX-2
expression scores between chronic hepatitis and cirrhosis
and also to evaluate COX-2 expression scores according to
the severity of hepatic fibrosis (Ishak's stage 1 to 3 vs. 4 to
6). Data are presented as the mean ± standard deviation
(SD). Significance was accepted when the p value was less
than 0.05.
Table 1.  Patient characteristics in chronic hepatitis and liver cirrhosis 
Chronic hepatitis  Liver cirrhosis   p value
a
(n = 43) (n = 24)
Gender (M/F) 29/14 18/6 > 0.05
Age, yr 42.3 ± 13.9 54.0 ± 11.1 0.001
ALT, IU/L                     129.5 ± 107.9 62.6 ± 61.8 0.002
Platelet, × 10
3/mm
3 193.9 ± 61.8 121.7 ± 49.6 < 0.001
Albumin, g/dL               3.9 ± 0.4 3.7 ± 0.4 0.048
PT (INR) 1.1 ± 0.1 1.2 ± 0.2 0.001
Bilirubin, mg/dL 0.8 ± 0.41 0.9 ± 0.43 > 0.05
AFP, ng/mL 19.9 ± 40.8 17.2 ± 26.7 > 0.05
ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalized ratio; AFP, alpha-fetoprotein.
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RESULTS
Patient characteristics
Patient characteristics are presented in Table 1. The
mean patient age was 46.5 ± 14.1 years. There were no
significant differences between the chronic hepatitis and
liver cirrhosis cohorts with regard to gender, bilirubin, or
alpha-fetoprotein (AFP) expression. However, significant
differences were observed for patient age, alanine
transaminase (ALT), platelets, albumin expression, and
prothrombin time (PT). 
COX-2 immunoreactivity
Hepatocyte cytoplasmic staining for COX-2 was noted
in cirrhotic and chronic hepatitis tissues as assessed by the




Figure 2. Immunohistochemical findings of cyclooxygenase-2 expression. Representative images depicting positive staining as scored
using two different scoring systems. Intensity scores of (A) 0 (negative, × 100); (B) 1 (weak, × 200); (C) 2 (moderate, × 200); and (D) 3
(strong, × 200). (E) A distribution score of 1 (focal) using Pazirandeh et al. [19] and 1 (1 to 25%) using Qiu et al. [31] (× 100). (F) A
distribution score of 2 (diffuse) using Pazirandeh et al. and 3 (51 to 75%) using Qiu et al. (× 100).368 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010
intensity score range from 0 to 3, and panels E and F show
the distribution scores from 0 to 2 based on the scoring
system of Pazirandeh et al. [19]. The latter can be
converted to 1 (1 to 25%) and 3 (51 to 75%), respectively, in
the system of Qiu et al. [31]. When COX-2 expression in
tissue samples from patients with chronic hepatitis (n =
43) and liver cirrhosis (n = 24) were assessed using the
two scoring systems, the correlation coefficient between
these two scoring systems was r = 0.965 (p< 0.001).
Comparison of COX-2 expression in chronic
hepatitis and cirrhosis
Mean COX-2 expression scores for chronic hepatitis
and liver cirrhosis were 2.5 ± 1.3 and 3.3 ± 1.1,
respectively, for sum 1 (p = 0.008), and 3.2 ± 2.0 and 4.5
± 1.7, respectively, for sum 2 (p = 0.006, Fig. 3). Using
both methods, COX-2 staining scores were significantly
different between the two groups. In terms of the
percentage of tissue samples showing high COX-2
Figure 3. Cyclooxygenase-2 (COX-2) expression scores in chronic hepatitis and cirrhosis. COX-2 expression scores in chronic
hepatitis and cirrhosis according to the scoring system of sum1 (A) and sum2 (B) as described in the Methods. 
a Student's t test.
Figure 4. High cyclooxygenase-2 (COX-2) expression in chronic hepatitis and cirrhosis. High COX-2 expression in chronic hepatitis
and cirrhosis according to the scoring system of sum1 and sum2 as described in the Methods. 
a Chi-square test.
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expression, a higher percentage of the cirrhosis group
stained positively for COX-2 compared with the chronic
hepatitis group. The percentage of chronic hepatitis and
cirrhosis samples with high COX-2 expression (score 4 to
5) based on sum 1 were 16.3% and 45.8%, respectively (p
= 0.022, Fig. 4), and 23.3% and 50.0%, respectively (p =
0.021, Fig. 4), based on sum 2 (score 5 to 7).
COX-2 expression and severity of hepatic fibrosis 
COX-2 expression scores based on the degree of hepatic
fibrosis according to Ishak's staging using the full range of
scores (from 1 to 6) revealed no significant differences in
sum 1 or sum 2 (r = 0.150, p > 0.05). However, when
scores of COX-2 expression was assessed according to
categorization based on low- vs. high-fibrosis stages
(Ishak's stages 1 to 3 vs. stages 4 to 6), COX-2 expression
scores for the stages 1 to 3 group and the stages 4 to 6
group were 2.4 ± 1.3 vs. 3.2 ± 1.1, respectively, for sum 1 (p
= 0.009), and 3.1 ± 2.0 vs. 4.3 ± 1.8, respectively, for sum
2 (p = 0.009 Fig. 5).
DISCUSSION
The present study demonstrated that COX-2 expression
is significantly higher in cirrhosis than in chronic
hepatitis, as well as in advanced fibrosis among all tissues,
suggesting that COX-2 is involved in the progression of
cirrhosis and fibrosis. This is the first report to definitively
show that COX-2 expression is higher in cirrhosis than in
chronic hepatitis using two scoring systems to validate the
results of the COX-2 expression scores. Sum 2 displayed a
wider range of staining scores and was better able to
identify faint differences in COX-2 expression in tissues
compared with sum 1, but it showed the same results as
those obtained using the sum 1 method. 
COX-2 expression has been reported to be upregulated
in chronic hepatitis, liver cirrhosis, and HCC [10,19] and is
thought to be a mediator of liver damage and liver
inflammation [32-34]. Pazirandeh et al. [19] reported a
significant difference in the mean COX-2 staining scores
between chronic hepatitis (2.2 ± 1.6) and cirrhosis (4.37 ±
1.15), as well as hepatocellular carcinoma (4.76 ± 0.54).
Based on staining scores, 81.5% of cirrhotic tissues
displayed a high COX-2 expression score (4 to 5) vs. only
17% of chronic hepatitis tissues [19]. In the present study,
the percentage of high COX-2 expression scores (4 to 5)
was 45.8% for liver cirrhosis and 16.3% for chronic
hepatitis based on sum 1 (p = 0.022) and 50.0% for liver
cirrhosis and 23.3% for chronic hepatitis according to sum
2 (p = 0.021). The reason for relatively low expression of
COX-2 in cirrhotic tissues in our study compared with
that of Pazirandeh et al. [19] is unclear. Patients with
hepatitis C dominated in the group evaluated by
Pazirandeh et al. (25 of 27 in the cirrhosis group), whereas
patients with hepatitis B were the majority in our study
(14 of 24 with hepatitis B vs. 7 of 24 with hepatitis C).
Compared with the results reported by Pazirandeh et al.,
Figure 5. Cyclooxygenase-2 (COX-2) expression scores according to the severity of hepatic fibrosis. COX-2 expression scores
according to the severity of hepatic fibrosis according to the scoring system of sum1 and sum2 as described in the methods. 
a Student's
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the percentage of samples showing high COX-2
expression in the hepatitis C group was lower in our study,
and the percentage of high COX-2 expression in the
hepatitis B group was higher. Specifically, the percentage
of high COX-2 expression scores (4 to 5) was 50.0% (7/14)
in the hepatitis B group and 14.3% (1/7) in the hepatitis C
group. However, any possible influence of viral etiology on
COX-2 expression cannot be compared directly because
the disease activity was different, despite their being
diseases of the same viral origin and same cirrhosis status.
Finally, besides the differences in the etiology of hepatitis
in each study, laboratory bias and racial and regional
factors may also have influenced COX-2 expression. 
COX-2 expression was also associated with the stage of
fibrosis. When we categorized tissue samples as low-
fibrosis (Ishak's score 1 to 3) and high-fibrosis stages
(Ishak's score 4 to 6), a significant correlation was
observed between COX-2 expression and the stage of
fibrosis. Although the correlation between COX-2
expression and individual stages 1 to 6 showed no
statistical significance, a significant increase in COX-2
expression was observed with high fibrosis when the
fibrosis stages were divided into two groups (stages 1 to 3
vs. 4 to 6). 
This study had the limitations associated with cross-
sectional research; although the findings demonstrated
high COX-2 expression in cirrhosis and advanced fibrosis,
the study could not demonstrate a causal relationship
between expression and disease.
The role of COX-2 in liver fibrosis is not fully
understood, although several investigators have reported
data from animal models demonstrating differential
efficacy of COX-2 inhibitors in this disease. Tu et al. [28]
reported that selective inhibition of COX-2 by rofecoxib in
vivo reduced portal hypertension and was associated with
antifibrotic activity. However, Hui et al. [23] demonstr-
ated that celecoxib potentiated experimental liver fibrosis
in rats, whereas Yu et al. [25] suggested that COX-2 did
not appear to mediate the development of liver fibrosis in
transgenic mice. The side effects of COX-2 inhibitors
include potential renal, gastrointestinal, and cardiov-
ascular events. Cardiovascular system safety is of
particular importance, as COX-2 inhibitors reportedly can
cause an increased risk of myocardial infarction [35].
Therefore, the US Food and Drug Administration has
removed two of these agents (valdecoxib and rofecoxib)
from the market. Additional investigations including an
animal study to assess the safety of selective COX-2
inhibitors and their effects on the progression of fibrosis
and development of HCC may be required. 
In conclusion, COX-2 expression was significantly
higher in cirrhosis compared with chronic hepatitis. When
we categorized the all study tissues into low- and high-
fibrosis stages, a significant association was observed
between COX-2 expression and the extent of fibrosis.
Thus, COX-2 may play a role in the progression of hepatic
fibrosis, and further study including an additional animal
study to investigate the effects of COX-2 inhibitors on
hepatic fibrosis may be warranted.
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